Latest / This Week In Medicine / 7 7 2025

Transcript

7 7 2025 · This Week In Medicine

• 0:00
  [SPEAKER_00]: Welcome to this week in medicine, your filtered medical journal summary.
• 0:03
  [SPEAKER_00]: Looking to stay up to date with the latest medical research but short on time?
• 0:07
  [SPEAKER_00]: This week in medicine has you covered.
• 0:09
  [SPEAKER_00]: Our AI-generated podcast provides you with a convenient, on the go solution to keep you informed about the most significant developments in the medicine field.
• 0:16
  [SPEAKER_00]: Each episode offers a filtered and concentrated summary of key journal articles, allowing you to stay informed without the need to sift through pages of research papers.
• 0:24
  [SPEAKER_00]: With this week in medicine, listening is faster than reading, and you can consume valuable medical knowledge while commuting, exercising, or during your daily routine.
• 0:32
  [SPEAKER_01]: Hi, this week in Medicine, we will be discussing.
• 0:35
  [SPEAKER_01]: First we will be discussing articles in New England Journal of Medicine.
• 0:39
  [SPEAKER_01]: Structured exercise after Ag event chemotherapy for colon cancer.
• 0:43
  [SPEAKER_01]: Background.
• 0:45
  [SPEAKER_01]: Preclinical and observational studies suggest that exercise may improve cancer outcomes, however, definitive level one evidence is lacking C.A.
• 0:53
  [SPEAKER_01]: conclusions.
• 0:54
  [SPEAKER_01]: A three-year structured exercise program initiated soon after adjuvant chemotherapy for colon cancer resulted in significantly longer disease-free survival and findings consistent with longer overall survival.
• 1:07
  [SPEAKER_01]: Next article.
• 1:08
  [SPEAKER_01]: Tearsepotide as compared with semiglutide for the treatment of obesity.
• 1:13
  [SPEAKER_01]: Background.
• 1:14
  [SPEAKER_01]: Tearsepotide and semiglutide are highly effective medications for obesity management.
• 1:20
  [SPEAKER_01]: The efficacy and safety of tiered cepatide as compared with semi-glutide in adults with obesity but without type two diabetes is unknown.
• 1:28
  [SPEAKER_01]: Conclusions.
• 1:29
  [SPEAKER_01]: Among participants with obesity but without diabetes, treatment with tired cepatide was superior to treatment with semi-glutide, with respect to reduction in body weight and waste circumference at week seventy-two.
• 1:42
  [SPEAKER_01]: Next article
• 1:43
  [SPEAKER_01]: Neal Agevint and Agevint Pembrollism app in locally advanced head and net cancer.
• 1:49
  [SPEAKER_01]: Background The benefit of the addition of perioperative Pembrollism app to standard care with surgery and adjuvant therapy for patients with locally advanced head and next Guamacel carcinoma, HNSCC, is unclear.
• 2:03
  [SPEAKER_01]: The addition of Neo-Agevent and Ag event Pembroll is a map to standard care significantly improved event-free survival among participants with locally advanced HNSCC.
• 2:13
  [SPEAKER_01]: Neo-Agevent Pembroll is a map did not affect the likelihood of surgical completion, known new safety signals were identified.
• 2:26
  [SPEAKER_01]: Next we will be discussing articles from Journal of American Medical Association.
• 2:30
  [SPEAKER_01]: Lerundra's stat in participants with uncontrolled hypertension and treatment resistant hypertension, the launch HTN randomized clinical trial.
• 2:39
  [SPEAKER_01]: Question, is the aldosterone synthase inhibitor Lerundra's stat more effective than placebo in reducing blood pressure in participants with uncontrolled hypertension?
• 2:49
  [SPEAKER_01]: including treatment resistant hypertension, taking two to five prescribed anti-hypertensive medications, findings.
• 2:56
  [SPEAKER_01]: In this randomized clinical trial, fifty milligrams of La Rundrestadt once daily significantly reduced automated office systolic blood pressure by sixteen.
• 3:05
  [SPEAKER_01]: nine millimeters HG versus placebo by seven.
• 3:09
  [SPEAKER_01]: nine millimeters HG.
• 3:10
  [SPEAKER_01]: At week six in participants taking two or more prescribed anti-hypertensive medications.
• 3:15
  [SPEAKER_01]: Lerundra stat was associated with a low incidence of hypercolemia and was well tolerated.
• 3:21
  [SPEAKER_01]: Meaning these data support the use of Lerundra stat as a treatment option for participants with uncontrolled hypertension, including treatment resistant hypertension.
• 3:36
  [SPEAKER_01]: Next we will be discussing articles from Annals of Internal Medicine.
• 3:40
  [SPEAKER_01]: Risk for stroke after newly diagnosed atrial fibrillation during hospitalization for other primary diagnoses.
• 3:48
  [SPEAKER_01]: A retrospective cohort study.
• 3:50
  [SPEAKER_01]: Background.
• 3:51
  [SPEAKER_01]: Atrial fibrillation, AF.
• 3:53
  [SPEAKER_01]: That is first diagnosed during hospitalization for other causes can subside with resolution of the inciting stressor, conclusion.
• 4:01
  [SPEAKER_01]: Among patients with newly diagnosed AF during hospitalization for other causes, a substantial proportion with low CHA-II DS-II VA scores receive anti-coagulation, with modest increases in this proportion at higher scores.
• 4:15
  [SPEAKER_01]: The stroke risk in patients with cha-to-DS-II VA scores greater than four approximated the two percent threshold commonly used to initiate anti-coagulation in AF.
• 4:32
  [SPEAKER_01]: Next, we will be discussing articles from British Medical Journal Global, Regional, and National Characteristics of the main causes of increased disease burden due to the COVID-nineteen pandemic objective too.
• 4:44
  [SPEAKER_01]: To quantify and identify the main causes of increased disease burden due to coronavirus disease, COVID-nineteen pandemic, conclusion.
• 4:54
  [SPEAKER_01]: The COVID-nineteen pandemic significantly increased the burden of several non-COVID conditions, particularly mental health disorders, malaria in young children in the African region, and stroke and eschemic heart disease in older adults, with notable disparities across age and sex.
• 5:10
  [SPEAKER_01]: These findings underscore the urgent need to strengthen health system resilience, enhance integrated surveillance, and adopt syndemic informed strategies to support equitable preparedness for future public health emergencies.
• 5:29
  [SPEAKER_01]: Next we will be discussing articles from Lancet.
• 5:32
  [SPEAKER_01]: Surgery vs. Cordacosteroid injection for carpal tunnel syndrome, districts, and open label, multi-center, randomized controlled trial.
• 5:41
  [SPEAKER_01]: Background.
• 5:42
  [SPEAKER_01]: Surgery and Cordacosteroid injections are established treatments for carpal tunnel syndrome, but the optimal treatment strategy remains unclear.
• 5:50
  [SPEAKER_01]: This study aimed to compare starting treatment with surgery versus starting with a corticosteroid injection interpretation.
• 5:57
  [SPEAKER_01]: In patients with carpal tunnel syndrome, initiating treatment with surgery offers a higher chance of recovery after eighteen months compared with starting with a corticosteroid injection, even with the possibility of additional interventions.
• 6:16
  [SPEAKER_01]: Next we will be discussing articles in the field of gastroenterology.
• 6:20
  [SPEAKER_01]: Here are the articles from gastroenterology.
• 6:23
  [SPEAKER_01]: Non-contrast magnetic resonance imaging versus ultrasoundography for hepatocelular carcinoma surveillance, a randomized single-center trial.
• 6:32
  [SPEAKER_01]: Background and aims.
• 6:34
  [SPEAKER_01]: This study aimed to compare ultrasoundography, U.S., and non-contrast magnetic resonance imaging, MRI, in the surveillance of hepatic malignancy, conclusions.
• 6:45
  [SPEAKER_01]: Non-contrast MRI is a better alternative to U.S.
• 6:48
  [SPEAKER_01]: for the surveillance of serotic patients offering earlier stage at initial diagnosis and lower false positive referral rate.
• 7:01
  [SPEAKER_01]: Here are the articles from clinical gastroenterology.
• 7:03
  [SPEAKER_01]: As a phagial expert development of a preliminary question prompt list for adults with eocinophilic esophagitis, a modified delphi study.
• 7:13
  [SPEAKER_01]: Background.
• 7:14
  [SPEAKER_01]: Question prompt lists, QPLs, are structured sets of disease-specific questions intended to encourage question asking by patients and enhanced patient physician communication.
• 7:24
  [SPEAKER_01]: To date, an O-specific QPL has not been developed for O-patient's conclusion dot's conclusion.
• 7:31
  [SPEAKER_01]: This is the first preliminary OQPL developed in the field of medicine.
• 7:35
  [SPEAKER_01]: We hope implementation enhances effective patient physician communication.
• 7:39
  [SPEAKER_01]: By encouraging patients to ask relevant questions that experts prioritize.
• 7:43
  [SPEAKER_01]: Future studies will aim to modify this communication tool by incorporating patient perspectives.
• 7:55
  [SPEAKER_01]: Next we will be discussing articles in the field of infectious diseases.
• 7:59
  [SPEAKER_01]: Here are the articles from clinical infectious diseases.
• 8:03
  [SPEAKER_01]: Glucocorticoid dosing and implications for vaccination, evolution of global definitions.
• 8:09
  [SPEAKER_01]: Despite widespread adoption of high dose glucocorticoid definitions across international immunization guidelines, E, prednisone equivalent dosing greater than twenty mg slash day,
• 8:20
  [SPEAKER_01]: Or greater than two MG-KG-slash-day in children, the rationale remains unclear.
• 8:25
  [SPEAKER_01]: Literature searches were performed through academic databases for this narrative review to identify relevant evidence regarding glucocorticoid dosing on vaccine responses and safety.
• 8:36
  [SPEAKER_01]: In people receiving prednesone less than seven MG-slash-day,
• 8:40
  [SPEAKER_01]: Vaccine responses are maintained in people on high dose glucocorticoids greater than twenty mg slash day antibody titers and seropositivity are reduced whereas the impact of low to medium dose glucocorticoids seven to twenty mg slash day on vaccine efficacy remains inconclusive due to inconsistent pediatric dosing regimens
• 9:02
  [SPEAKER_01]: Data is insufficient to support a unified high dose glucocorticoid threshold.
• 9:07
  [SPEAKER_01]: Non-live vaccines are well tolerated in patients receiving glucocorticoids with rheumatic slash inflammatory disorders, but enhanced reactogenicity after live vaccination may occur in those with severe immunodeficiencies.
• 9:20
  [SPEAKER_01]: Clinicians should consider individual risk benefit profiles, rather than following strict dosing thresholds, when curating immunization programs for patients prescribed glucocorticoids.
• 9:36
  [SPEAKER_01]: Next we will be discussing articles in the field of rheumatology.
• 9:40
  [SPEAKER_01]: Here are the articles from Journal of Clinical rheumatology.
• 9:43
  [SPEAKER_01]: Association of Cloto and Gout in Middle-aged and older adults, National Health and Nutrition Survey, two thousand seven to twenty sixteen background.
• 9:53
  [SPEAKER_01]: Cloto, which is known to negatively regulate metabolic disorders and kidney disease, has a role in gout that remains unclear.
• 10:00
  [SPEAKER_01]: This research explored how Cloto levels correlate with the prevalence of gout conclusions.
• 10:06
  [SPEAKER_01]: This research found a negative correlation between serum alpha-cloto concentrations and the occurrence of gout.
• 10:12
  [SPEAKER_01]: Those with the highest levels of cloto exhibited the lowest likelihood of gout, indicating potential importance for future studies and clinical uses.
• 10:27
  [SPEAKER_01]: Next we will be discussing articles in the field of cardiology.
• 10:30
  [SPEAKER_01]: Here are the articles from Circulation.
• 10:33
  [SPEAKER_01]: FMO-II prevents pathological cardiac hypertrophy by maintaining the ER mitochondria association through interaction with IP-III.
• 10:42
  [SPEAKER_01]: R-II-G-R-P-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-
• 10:59
  [SPEAKER_01]: We reported that FMO-II localizes to mitochondria associated endoplasmic reticulum membranes, where it binds to anocytal one comma four comma five tricephosphate type two receptor.
• 11:11
  [SPEAKER_01]: IP-three R-II, to maintain the endoplasmic reticulum mitochondria contacts, thereby regulating mitochondrial caught two plus signaling for bio-energetics.
• 11:27
  [SPEAKER_01]: Here are the articles from journals of the American College of Cardiology.
• 11:31
  [SPEAKER_01]: Long acting factor eleven inhibition and paraprocedural bleeding, an analysis from Azalea Timmy-Seventy-One.
• 11:38
  [SPEAKER_01]: Backgrounded.
• 11:39
  [SPEAKER_01]: In Azalea Timmy-Seventy-One, a multi-center, randomized, active controlled study to evaluate the safety and tolerability of two blinded doses of a bellishy mob, compared with open label Riveroxaban.
• 11:52
  [SPEAKER_01]: In patients with atrial fibrillation, thrombolysis, and myocardial infarction-seventy-one, abolashimab, a novel factor-eleven inhibitor, significantly reduced the rate of major or clinically relevant non-major, CRNM, bleeding compared with river oxaban and patients with atrial fibrillation AF.
• 12:11
  [SPEAKER_01]: Abalashimab is long acting with a half-life of twenty-eight days conclusions.
• 12:16
  [SPEAKER_01]: These data illustrate that patients with AF treated with abalashimab, a long acting factor eleven inhibitor, can undergo invasive procedures with low rates of bleeding.
• 12:26
  [SPEAKER_01]: Moreover, these findings suggest that routine interruption of anticoagulation may not be necessary for all procedures in the context of factor eleven inhibition, particularly for procedures that have low bleeding risks.
• 12:44
  [SPEAKER_01]: from Jamacardiology.
• 12:46
  [SPEAKER_01]: Cardiomyopathy associated gene variants in atrial fibrillation.
• 12:50
  [SPEAKER_01]: Question.
• 12:51
  [SPEAKER_01]: What are the prevalence and clinical implications of inherited cardiomyopathy associated pathogenic or likely pathogenic?
• 12:58
  [SPEAKER_01]: CMPPLP.
• 13:00
  [SPEAKER_01]: Variants in patients with atrial fibrillation, AF?
• 13:04
  [SPEAKER_01]: Findings.
• 13:05
  [SPEAKER_01]: In two longitudinal cohorts, including a total of forty-four one hundred eighty-two patients with AF.
• 13:11
  [SPEAKER_01]: The frequency of CMPPLP variance was two-fold higher in patients with AF, and up to five-fold in early onset AF, less than forty-five years.
• 13:20
  [SPEAKER_01]: Patients with CMP PLP positive AF were at increased risk of incident cardiomyopathy or heart failure.
• 13:28
  [SPEAKER_01]: CMP slash HF after AF diagnosis, meaning results suggest that CMP PLP variants could be discovered by genetic testing in up to five percent of patients with AF and could identify patients with AF who are at higher risk for CMP slash HF.
• 13:51
  [SPEAKER_01]: Next we will be discussing articles in the field of endocrinology.
• 13:55
  [SPEAKER_01]: Here are the articles from Journal of Clinical Endocrinology and Metabolism.
• 13:59
  [SPEAKER_01]: Cost effectiveness analysis comparing conventional and digital software supported management for hypothyroidism.
• 14:06
  [SPEAKER_01]: Background
• 14:07
  [SPEAKER_01]: Wearable devices can now leverage the established correlation between thyroid function and heart rate to monitor thyroid function alongside exercise levels and heart rate.
• 14:17
  [SPEAKER_01]: The objective was to assess the cost effectiveness of introducing a wearable slash mobile-based thyroid function digital monitoring solution for the management of hypothyroidism compared to the conventional management approach tons conclusion.
• 14:30
  [SPEAKER_01]: The incorporation of the digital monitoring solution has demonstrated positive cost effectiveness in hypothyroidism management when compared to the standard care.
• 14:39
  [SPEAKER_01]: The cost of the digital monitoring solution and its sensitivity are key factors in determining cost effectiveness, striking a balance among the cost of digital monitoring support, the precision of hormonal level monitoring, and its effectiveness for the specific group of hypothyroid patients in real-world clinical practice is essential.
• 15:04
  [SPEAKER_01]: Here are the articles from diabetes care.
• 15:06
  [SPEAKER_01]: Impact of eyelid transplantation on diabetes complications and mortality in patients living with type one diabetes.
• 15:14
  [SPEAKER_01]: Objective.
• 15:15
  [SPEAKER_01]: This study aims to evaluate the impact of eyelid transplantation, IT.
• 15:20
  [SPEAKER_01]: on diabetes complications, death and cancer incidents.c conclusions.
• 15:25
  [SPEAKER_01]: This study suggests long-term benefits of IT on diabetes-related outcomes.
• 15:30
  [SPEAKER_01]: Furthermore, despite the use of immunosuppressive drugs following IT, we observed no significant increase in the risk of cancer.
• 15:38
  [SPEAKER_01]: All together, these findings highlight a favorable risk-benefit ratio of IT in treating patients with unstable T-one D.
• 15:51
  [SPEAKER_01]: Next we will be discussing articles in the field of neurology.
• 15:55
  [SPEAKER_01]: Here are the articles from neurology.
• 15:57
  [SPEAKER_01]: Association of predicted visceral fat percentage with dementia risk and older adults, the role of genetic risk and lifestyle.
• 16:05
  [SPEAKER_01]: Background and objectives
• 16:07
  [SPEAKER_01]: obesity is a modifiable dementia risk factor.
• 16:11
  [SPEAKER_01]: But body mass index does not account for fat distribution, particularly visceral fat, which is more strongly linked to metabolic and cardiovascular health.
• 16:20
  [SPEAKER_01]: Despite its relevance, research on visceral fat and dementia is limited, especially in large-scale prospective studies.
• 16:27
  [SPEAKER_01]: The aim of this study was to assess the association between visceral fat and dementia risk.
• 16:32
  [SPEAKER_01]: It's interaction with genetic predisposition.
• 16:35
  [SPEAKER_01]: And the impact of healthy lifestyle adherence discussion.
• 16:39
  [SPEAKER_01]: Among non-demented community dwelling older Britons, a typical VFP was associated with higher dementia risk in both sexes, the lack of interaction between VFP and genetic risk highlights the complexity of dementia pathogenesis.
• 16:53
  [SPEAKER_01]: In addition, a healthy lifestyle may mitigate the dementia risk associated with atypical VFP levels.
• 17:06
  [SPEAKER_01]: Next we will be discussing articles in the field of pulmonary and critical care.
• 17:10
  [SPEAKER_01]: Here are the articles from chest.
• 17:12
  [SPEAKER_01]: Ventilator associated pneumonia in low and middle income versus high income countries.
• 17:18
  [SPEAKER_01]: Background.
• 17:19
  [SPEAKER_01]: Ventilator associated pneumonia.
• 17:21
  [SPEAKER_01]: VAP, rates are higher in low and middle-income countries, LMAX, than in high-income countries, HICS, research question.
• 17:30
  [SPEAKER_01]: Could differences in ventilator bundle adherence, ventilation practices, and critical care staffing be driving variations in VAP risk between LMAX and HICS, interpretation?
• 17:41
  [SPEAKER_01]: Our results show that patients in LMAX have a two-fold higher risk of VAP.
• 17:45
  [SPEAKER_01]: Independent of bundle adherence, prolonged mechanical ventilation was an independent predictor of VAP.
• 17:51
  [SPEAKER_01]: Whereas higher staffing ratios were associated with decreased risk for vape development, unmeasured factors, e.g., infrastructure, infection control practices may explain the higher evaporates and elements.
• 18:09
  [SPEAKER_01]: Here are the articles from the American Journal of Respiratory and Critical Care Medicine.
• 18:14
  [SPEAKER_01]: Early versus delayed switching from controlled to assisted ventilation, a target trial emulation.
• 18:20
  [SPEAKER_01]: Rational, in critically ill patients receiving invasive mechanical ventilation, switching from controlled to assisted ventilation is a crucial milestone toward ventilator liberation.
• 18:31
  [SPEAKER_01]: The optimal timing for switching to assisted ventilation has not been studied.
• 18:35
  [SPEAKER_01]: Conclusions.
• 18:36
  [SPEAKER_01]: Early switching from controlled to assisted ventilation is associated with shorter duration of invasive mechanical ventilation and ICU stay compared with delayed switching.
• 18:52
  [SPEAKER_01]: Next we will be discussing articles in the field of nephrology.
• 18:56
  [SPEAKER_01]: Here are the articles from Clinical Journal of American Society of Nephrology.
• 19:00
  [SPEAKER_01]: High heat exposure and medical utilization among the CKD population.
• 19:05
  [SPEAKER_01]: Exposure to days with higher heat indices was associated with increases in weekly utilization for a population with CKD.
• 19:13
  [SPEAKER_01]: Higher heat indices were associated with a larger increase in kidney related visits than all cause utilization.
• 19:19
  [SPEAKER_01]: Higher heat indices were associated with larger effects on kidney related emergency department use for those least likely to have air conditioning.
• 19:33
  [SPEAKER_01]: Here are the articles from kidney international reports.
• 19:37
  [SPEAKER_01]: Effective sleep characteristics on rapid estimated GFR decline in adults with normal kidney function.
• 19:43
  [SPEAKER_01]: Introduction This study was conducted to evaluate the association between self-reported sleep characteristics and rapid decline of estimated glomerular filtration rate, EGFR, in adults with initially normal kidney function, conclusion.
• 19:58
  [SPEAKER_01]: Regular daytime napping, especially in older adults, may be protective against kidney function decline, whereas short sleep duration may accelerate egg for decline in younger adults.
• 20:09
  [SPEAKER_01]: Addressing sleep habits may aid in preventing chronic kidney disease, CKD.
• 20:14
  [SPEAKER_00]: Thank you for listening to this week in medicine, your filtered medical journal summary.
• 20:18
  [SPEAKER_00]: Have a great week ahead, stay blessed and be humane.